Canaccord Genuity Group Reiterates Buy Rating for Health Catalyst (NASDAQ:HCAT)

Canaccord Genuity Group reissued their buy rating on shares of Health Catalyst (NASDAQ:HCAT – Free Report) in a research note published on Tuesday morning, Benzinga reports. Canaccord Genuity Group currently has a $11.00 price objective on the stock. Other equities research analysts have also recently issued research reports about the stock. Guggenheim upgraded shares of […]

Related Keywords

United States ,Piper Sandler ,Institutional Trading Of Health Catalyst ,News Ratings For Health Catalyst Daily ,Vanguard Group Inc ,York Mellon Corp ,Health Catalyst Inc ,Health Catalyst Stock Performance ,Health Catalyst ,Canaccord Genuity Group ,Analyst Recommendations For Health Catalyst ,Wells Fargo Company ,Nasdaq ,Valmark Advisers Inc ,Nepsis Inc ,Cantor Fitzgerald ,Free Report ,Genuity Group ,Wells Fargo ,Moderate Buy ,Get Free Report ,New York Mellon Corp ,Health Catalyst Daily ,